These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26064053)

  • 1. A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation.
    Anand E; Berggren L; Deix C; Tóth Á; McDonnell DP
    Neuropsychiatr Dis Treat; 2015; 11():1349-57. PubMed ID: 26064053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.
    McDonnell DP; Landry J; Detke HC
    Int Clin Psychopharmacol; 2014 Nov; 29(6):322-31. PubMed ID: 24850228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
    Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D
    Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.
    McDonnell DP; Detke HC; Bergstrom RF; Kothare P; Johnson J; Stickelmeyer M; Sanchez-Felix MV; Sorsaburu S; Mitchell MI
    BMC Psychiatry; 2010 Jun; 10():45. PubMed ID: 20537130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia.
    Detke HC; Weiden PJ; Llorca PM; Choukour M; Watson SB; Brunner E; Ascher-Svanum H
    J Clin Psychopharmacol; 2014 Aug; 34(4):426-34. PubMed ID: 24781441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting injectable antipsychotics: focus on olanzapine pamoate.
    Lindenmayer JP
    Neuropsychiatr Dis Treat; 2010 Jun; 6():261-7. PubMed ID: 20628628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS).
    Novakovic V; Adel T; Peselow E; Lindenmayer JP
    Clin Neuropharmacol; 2013; 36(2):59-62. PubMed ID: 23503549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study.
    Meyers KJ; Upadhyaya HP; Landry JL; Chhabra-Khanna R; Falk DM; Seetharama Rao B; Jones ME
    BJPsych Open; 2017 Jul; 3(4):186-192. PubMed ID: 28811926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study.
    Jones ME; Andrews JS; Faries DE; Landry J; Xu J; Detke HC; Chhabra-Khanna R; McDonnell DP
    BMC Psychiatry; 2015 Nov; 15():278. PubMed ID: 26567159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost-effectiveness study of olanzapine pamoate: Mirror-image analysis after one year].
    Potaufeu J; Langrée B; Drapier D; Burgot G; Marie N
    Encephale; 2019 Jun; 45(3):232-238. PubMed ID: 30579574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being.
    Anand E; Berggren L; Landry J; Tóth Á; Detke HC
    Neuropsychiatr Dis Treat; 2016; 12():2737-2743. PubMed ID: 27822046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.
    Detke HC; McDonnell DP; Brunner E; Zhao F; Sorsaburu S; Stefaniak VJ; Corya SA
    BMC Psychiatry; 2010 Jun; 10():43. PubMed ID: 20537128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.
    Lauriello J; Lambert T; Andersen S; Lin D; Taylor CC; McDonnell D
    J Clin Psychiatry; 2008 May; 69(5):790-9. PubMed ID: 18452346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.
    Bushe CJ; Falk D; Anand E; Casillas M; Perrin E; Chhabra-Khanna R; Detke HC
    BMC Psychiatry; 2015 Apr; 15():65. PubMed ID: 25886006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine Pamoate Use for Schizophrenia: Retrospective Records Based Study from a Tertiary Care Hospital.
    Grover S; Singla H; Chakrabarti S; Avasthi A
    Indian J Psychol Med; 2020; 42(2):162-167. PubMed ID: 32346258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation.
    Samalin L; Garay R; Ameg A; Llorca PM
    Expert Opin Drug Saf; 2016; 15(3):403-11. PubMed ID: 26761429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection.
    Ascher-Svanum H; Novick D; Haro JM; Bertsch J; McDonnell D; Detke H
    Neuropsychiatr Dis Treat; 2014; 10():1125-31. PubMed ID: 25018631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia.
    Mamo D; Kapur S; Keshavan M; Laruelle M; Taylor CC; Kothare PA; Barsoum P; McDonnell D
    Neuropsychopharmacology; 2008 Jan; 33(2):298-304. PubMed ID: 17443131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.
    Hill AL; Sun B; McDonnell DP
    Clin Schizophr Relat Psychoses; 2014 Jan; 7(4):216-22. PubMed ID: 23428782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia.
    Ascher-Svanum H; Peng X; Montgomery W; Faries DE; Lawson AH; Witte MM; Novick D; Jemiai N; Perrin E; McDonnell DP
    Eur Psychiatry; 2011; 26(5):313-9. PubMed ID: 20621454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.